中国实用内科杂志2025，Vol.45Issue(6)：471-476,6.DOI:10.19538/j.nk2025060104
晚期肺癌个体化免疫治疗疗效与免疫相关不良反应的平衡策略
Strategies for balancing the efficacy and immune-related adverse events in personalized immunotherapy for advanced lung cancer
王李强 1谢晓鸿 1林心情 1周承志1
作者信息
- 1. 呼吸疾病国家重点实验室,呼吸疾病国家临床研究中心,广州呼吸健康研究院,前沿交叉学科研究中心重点实验室,广州医科大学附属第一医院呼吸与危重症医学科,广东 广州 510120
- 折叠
摘要
Abstract
Immune checkpoint inhibitors(ICIs)have significantly increased the efficacy of treatment for advanced lung cancer,but at the same time,they also increase the risks of immune-related adverse events(irAEs).The occurrence of irAEs is closely related to the efficacy,but improper management may severely affect the prognosis and quality of life of the patients.In individualized immunotherapy for advanced lung cancer,it is possible to achieve dynamic balance between treatment efficacy and safety through multidimensional risk assessments,multi-omics data-integrated prediction,refined staging management,and dynamic monitoring and warning.Multidisciplinary team collaboration and patient education are very important,and telemedical technologies are of some value in the long-term follow-up and immunotherapeutic rechallenge.In the future,the application of artificial intelligence technologies is promising in further enhancing precision and safety of immunotherapy.关键词
晚期肺癌/个体化免疫治疗/免疫检查点抑制剂/免疫相关不良反应Key words
advanced lung cancer/personalized immunotherapy/immune checkpoint inhibitors/immune-related adverse events分类
临床医学引用本文复制引用
王李强,谢晓鸿,林心情,周承志..晚期肺癌个体化免疫治疗疗效与免疫相关不良反应的平衡策略[J].中国实用内科杂志,2025,45(6):471-476,6.
